Abstract
Vaccines derived from human adenoviruses (HAdV) are currently being used and trialed against numerous infectious agents. However, pre-existing humoral immunity can impair vaccines efficacy and safety. Strategies to circumvent this immunity often involve the use of vectors with lower seroprevalence. We evaluated HAdV-C5, HAdV-D26 and HAdV-B35 seroprevalence from healthy and HIV-infected populations from Burkina Faso and Chad. Seroprevalence for HAdV-C5 was high and comparable between countries (54%-66%), and the highest in the HIV-infected groups from sub-Saharan regions (∼90%). However, compared to France (4%), seroprevalence for HAdV-D26 was significantly higher in sub- Saharan groups (∼47%). By contrast, HAdV-B35 seroprevalence was low for all groups tested. We also found that HAdV-D26 complexed with immunoglobulins induced strong activation of dendritic cells in vitro. Our study fills gaps in the epidemiological data needed to optimize HAdV-derived vaccines in sub-Saharan regions, and highlights the necessity to better adjust vaccination strategies in Africa.
Article summary line HAdVs Seroprevalence in Burkina Faso and Chad
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by - University of Montpellier (EJK) - Pierre Fabre Foundation (FJDM) - National Institute of Health and Medical Research (INSERM) (PVDP) - The University Hospital Complex of Montpellier (ET) - University Hospital Complex Le Bon Samaritain (GTZ) - Centre MURAZ (ARO) - The French Ministry of Higher Education (OP)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Centre MURAZ gave Number 2017-361/MS/SG/CM/DG approval for this work. IRB of the National Malaria Research and Training Center gave AEP-04/07/20 1O/CIB-CNRFP approval for this work. IRB of the Occitanie & Midi-Pyrenees EFS gave EFS-OCPM: Number 21PLER2019-0002 approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵2 Co-senior authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.
